The Cost-Adherence Problem with Brilinta

You've prescribed Brilinta (Ticagrelor) because the evidence supports it — superior outcomes compared to Clopidogrel in ACS, consistent efficacy regardless of CYP2C19 status, and reversible platelet inhibition that offers surgical flexibility. But none of that matters if your patient can't afford to fill the prescription.

Cost-related non-adherence is one of the biggest threats to outcomes in antiplatelet therapy. Studies consistently show that patients who face high out-of-pocket costs for cardiovascular medications are significantly more likely to skip doses, split pills, or abandon treatment entirely. For a drug with a boxed warning about the risks of premature discontinuation — including increased rates of MI, stroke, and death — the stakes couldn't be higher.

This guide gives you the practical tools to help your patients navigate Brilinta's cost landscape in 2026, so that the medication you prescribe is the medication they actually take.

What Your Patients Are Actually Paying

Understanding the numbers helps you anticipate which patients will struggle and proactively address cost barriers:

• Brand-name Brilinta (cash price): $450–$665 per month for 60 tablets (either 60 mg or 90 mg strength)
• Generic Ticagrelor (cash price): Approximately $430 per month at retail without discount. With discount cards (GoodRx, SingleCare, etc.): $30–$100 per month
• With commercial insurance: Typically Tier 3 formulary placement. Copays vary widely — anywhere from $10 to $100+ depending on the plan
• With Medicare Part D: Covered on most formularies, but patients in the coverage gap ("donut hole") may face significant out-of-pocket costs. Generic availability has improved this substantially
• Uninsured / underinsured: Without any discount program, patients face the full retail price. This is where intervention makes the biggest difference

The good news: the generic Ticagrelor market matured significantly in 2025–2026, with multiple manufacturers (Alembic, Novadoz, Ascend, Teva, Hisun Pharmaceuticals) driving prices down. For most patients, generic is the first-line cost solution.

Manufacturer Savings Programs

AstraZeneca Brilinta Savings Card

For patients who specifically need brand-name Brilinta (whether by preference, formulary requirement, or clinical need), AstraZeneca offers a copay savings card:

• Eligibility: Commercially insured patients. Medicare, Medicaid, and government-insured patients are not eligible
• Savings: Eligible patients may pay as little as $5 per 30-day supply
• Maximum benefit: Up to $200 savings per fill
• For cash-pay or insurance-restricted patients: A separate savings offer may provide up to $100 off per 30-day supply

The card can be downloaded directly from AstraZeneca's website or your office can keep printed cards available. Consider having your team proactively hand these to patients at the point of prescribing.

AZ&Me Patient Assistance Program — No Longer Covers Brilinta

An important update: as of January 1, 2026, Brilinta was removed from AstraZeneca's AZ&Me patient assistance program. This was likely driven by the availability of generic alternatives. Patients who previously relied on this program need to be transitioned to generic Ticagrelor or alternative assistance sources.

Coupon and Discount Card Programs

For generic Ticagrelor, discount cards are often the most impactful cost-reduction tool. These are free, require no insurance, and can be used at most pharmacies:

• GoodRx: Widely recognized, consistently offers competitive pricing for generic Ticagrelor. Prices typically range from $30–$80 depending on pharmacy and quantity
• SingleCare: Another reliable option with similar savings. Often competitive at Walmart and CVS
• RxSaver: Compares prices across pharmacies in the patient's area
• Optum Perks: Good option for patients in UnitedHealth-affiliated networks
• BuzzRx: Free discount card with consistent savings on generics

A practical workflow: when prescribing Brilinta/Ticagrelor, direct patients to check GoodRx or SingleCare for the best price at their preferred pharmacy before filling. A two-minute conversation at the point of care can save them hundreds of dollars per month.

For patients who need more options, our patient-facing savings guide walks through all available programs.

Generic Alternatives and Therapeutic Substitution

Generic Ticagrelor

Generic Ticagrelor is the single biggest cost lever for most patients. Key points for your prescribing workflow:

• Bioequivalence: FDA-approved generics meet the same bioequivalence standards as brand-name Brilinta. Clinically interchangeable
• Availability: Multiple manufacturers as of mid-2025 — Alembic, Novadoz, Ascend, Teva, and Hisun Pharmaceuticals. Both 60 mg and 90 mg strengths available
• Cost: $30–$100/month with discount cards vs. $450–$665/month for brand Brilinta
• Prescribing tip: Write prescriptions as "Ticagrelor" (generic name) and allow substitution unless you have a specific clinical reason to require brand

Therapeutic Alternatives (When Ticagrelor Isn't Feasible)

If cost remains prohibitive even with generic Ticagrelor, consider whether a therapeutic switch is clinically appropriate:

• Clopidogrel (Plavix): Generic Clopidogrel is extremely affordable ($4–$15/month at most pharmacies). For patients without CYP2C19 loss-of-function alleles and without contraindications, Clopidogrel is a reasonable alternative — particularly for lower-risk patients or those beyond the acute phase. Consider CYP2C19 testing if switching from Ticagrelor to Clopidogrel
• Prasugrel (Effient): Generic Prasugrel is available and moderately priced. More potent than Clopidogrel but carries higher bleeding risk. Not recommended for patients over 75 or those with prior stroke/TIA. Once-daily dosing may improve adherence

Document your clinical rationale for any therapeutic substitution, and ensure patients understand the change.

Alternative Assistance Resources

For patients who fall through the cracks — uninsured, Medicare coverage gaps, or financial hardship — these organizations may help:

• NeedyMeds (needymeds.org) — Database of patient assistance programs, discount drug cards, and state-specific resources
• RxAssist (rxassist.org) — Comprehensive database of pharmaceutical assistance programs
• RxHope (rxhope.com) — Helps patients apply for manufacturer and independent assistance programs
• State pharmaceutical assistance programs (SPAPs) — Many states offer supplemental drug coverage for residents who meet income requirements. Eligibility varies by state

Building Cost Conversations into Your Workflow

The most effective cost interventions happen proactively, not reactively. Here are practical strategies for integrating cost awareness into your prescribing workflow:

At the Point of Prescribing

• Ask about cost concerns directly: "Can you tell me about your insurance coverage for medications? I want to make sure we find an option you can afford."
• Prescribe generic by default: Write "Ticagrelor" unless brand is clinically required. This gives the pharmacy maximum flexibility to fill with the lowest-cost option
• Provide savings resources proactively: Hand patients the AstraZeneca savings card (for commercially insured brand users) or direct them to GoodRx/SingleCare for generic. Don't wait for them to ask
• Flag the risk of stopping: Explicitly tell patients that cost should never be a reason to stop or skip Brilinta without calling your office first. "If you can't afford a refill, call us before you run out — we can help find a solution"

At Follow-Up Visits

• Ask about adherence and cost: "Have you been able to fill your Ticagrelor each month? Any issues with cost or availability?"
• Review what they're paying: Patients' insurance situations change — job loss, plan changes, entering the Medicare donut hole. Check in periodically
• Adjust as needed: If a patient is struggling, this is the time to consider generic substitution, discount cards, or therapeutic alternatives

Staff and System-Level Strategies

• Train your front-desk and nursing staff to provide savings card information and basic discount card guidance
• Keep printed savings cards for commonly prescribed brand medications at the checkout area or in discharge packets
• Use your EHR's formulary checker to identify coverage issues before the patient leaves the office
• Partner with your pharmacy team to flag patients whose fills are delayed or abandoned due to cost

Using Medfinder in Your Practice

For providers looking to help patients locate pharmacies with Brilinta or generic Ticagrelor in stock — especially when specific manufacturers or strengths are hard to find — Medfinder for Providers can be a useful resource. It helps bridge the gap between prescribing and filling by showing real-time pharmacy availability.

If you're a provider interested in tools that help your patients find and afford their medications, visit medfinder.com/providers.

Final Thoughts

The evidence for Ticagrelor in ACS, post-MI secondary prevention, and acute ischemic stroke is strong. But evidence-based prescribing only translates to outcomes when patients can consistently access and afford their medications.

In 2026, the landscape is actually favorable: generic Ticagrelor is widely available at a fraction of the brand cost, discount cards can bring monthly expenses under $50 for most patients, and manufacturer savings cards still cover commercially insured patients on brand Brilinta.

The providers who get the best outcomes are the ones who treat cost as a clinical variable — not an afterthought. A brief, proactive cost conversation at the point of prescribing can be the difference between a patient who stays on therapy and one who silently stops.

For additional clinical and patient-facing resources on Brilinta, explore our guides on shortage updates for providers, helping patients find Brilinta in stock, and drug interactions.